However, further studies are required from pathologically (alpha-synuclein, phospho-tau, total-tau and amyloid) and cognitively characterized cohorts using medication and pathology-free, age-matched control groups to elucidate how these measures correlate with symptom severity and are influenced by Alzheimer’s disease and Parkinson’s disease pathology. This evidence concerns the gene SNCA and Parkinson disease.